Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica RemediaLTS:0M8I 58 Return-on-Tangible-Equity is 3.42% as of Mar. 2026, which is 65% below its 10-year median of 9.81. GuruFocus rates LTS:0M8I with a GF Score™ of 58/100 and a GF Value™ of lei0.23. The stock has 8 warning signs investors should review. Among 111 Medical Distribution companies, Farmaceutica Remedia ranks worse than 54.95% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Farmaceutica Remedia's annualized net income for the quarter that ended in Mar. 2026 was lei2.7 Mil. Farmaceutica Remedia's average shareholder tangible equity for the quarter that ended in Mar. 2026 was lei78.4 Mil. Therefore, Farmaceutica Remedia's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 3.42%.
The historical rank and industry rank for Farmaceutica Remedia's Return-on-Tangible-Equity or its related term are showing as below:
LTS:0M8I'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.9 Med: 9.81 Max: 61.25
Current: 7.82
During the past 13 years, Farmaceutica Remedia's highest Return-on-Tangible-Equity was 61.25%. The lowest was 3.90%. And the median was 9.81%.
LTS:0M8I's Return-on-Tangible-Equity is ranked worse than 54.95% of 111
companies
in the Medical Distribution industry
Industry Median: 8.78
vs LTS:0M8I: 7.82
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Farmaceutica Remedia Return-on-Tangible-Equity Related Terms
Farmaceutica Remedia Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0M8I vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 3.42% mean?
Farmaceutica Remedia (LTS:0M8I) has a Return-on-Tangible-Equity of 3.42% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Farmaceutica Remedia and its competitors. This is 65% below median its historical median of 9.81. Over the past decade, Farmaceutica Remedia's Return-on-Tangible-Equity has ranged from 3.90 to 61.25. According to the industry distribution chart, Farmaceutica Remedia ranks #61 out of 111 companies in the Medical Distribution industry, placing it in the top 55%.
Is Farmaceutica Remedia's Return-on-Tangible-Equity too high?
Farmaceutica Remedia's current Return-on-Tangible-Equity of 3.42% is 65% below median its 10-year median of 9.81. Over the past 10 years, this metric has ranged from a low of 3.90 to a high of 61.25. The Medical Distribution industry median Return-on-Tangible-Equity is 8.78. Farmaceutica Remedia's value of 3.42% is 61% below this industry median. Based on the distribution chart, Farmaceutica Remedia ranks #61 out of 111 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Farmaceutica Remedia has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #61 out of 111 companies for Return-on-Tangible-Equity. This places Farmaceutica Remedia in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.78. Farmaceutica Remedia's value of 3.42% is 61% below this benchmark. Historically, Farmaceutica Remedia's own Return-on-Tangible-Equity has ranged from 3.90 to 61.25 over the past decade. While the company's 10-year median is 9.81 vs. the industry median of 8.78, Farmaceutica Remedia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.78, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmaceutica Remedia's current Return-on-Tangible-Equity of 3.42% is 61% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current Return-on-Tangible-Equity is 3.42%, which is 65% below median its own 10-year median of 9.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Farmaceutica Remedia (LTS:0M8I) has a current Return-on-Tangible-Equity of 3.42%. The stock's GF Value™ is lei0.23, compared to a current price of lei0.25 — trading 8.7% above its estimated fair value. The current Return-on-Tangible-Equity is 3.42%, which is 65% below median its 10-year median of 9.81 and 61% below the Medical Distribution industry median of 8.78. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Farmaceutica Remedia (LTS:0M8I), the current Return-on-Tangible-Equity is 3.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (LTS:0M8I) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.25 is trading 8.7% above its estimated GF Value™ of lei0.23.
Key valuation signals for LTS:0M8I:
Return-on-Tangible-Equity: 3.42% (65% below median its 10-year median of 9.81)
GF Value™: lei0.23 vs. price of lei0.25 (8.7% above fair value)
Industry Position: 61% below the Medical Distribution median (#61 of 111)
No single metric tells the full story. See the LTS:0M8I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score
Get the complete analysis for LTS:0M8I
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M8I has been successfully added to your 
